The effect of oral Kallikrein treatment on sperm motility in asthenozoospermia

Abstract
Nineteen men with asthenozoospermia were treated with oral Kallikrein (600 U daily for 12 wk) and sperm motility evaluated in 16 of these patients. No quantitative or qualitative improvement in motility or the duration of motility was found in semen samples examined 4, 12 and 24 wk after starting the treatment. Two pregnancies occurred 11 and 40 wk after discontinuation of the Kallikrein therapy.